$VAPR E-Cite Motors Receives 75 Million Dollar Valuation by

New Post Public Reply Private Reply Replies (0) Message Board
louied91
255
$VAPR E-Cite Motors Receives 75 Million Dollar Valuation by Industry Experts for Production Vehicle Offering Contained in Documents Filed with the SEC Amidst CARB Approval to Proceed with Certification

https://www.globenewswire.com/news-release/20...d-wit.html

BOTHELL, WA, May 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – E-Cite Motors Group (OTCPK:VAPR), a privately held subsidiary of VaporBrands International, Inc., announced that it has received a pre-money valuation of Seventy Five Million Dollars for the purpose of raising capital for the manufacturing of its production vehicles.

The valuation was ratified in filings with the Securities and Exchange Commission (Form C) which will allow any retail investor and the general public to invest directly into E-Cite Motors L.L.C. for the purpose of financing the manufacturing of its production vehicles expected to be in its dealership showroom Q4 2023. The valuation was determined by a consensus of industry experts specializing in JOBS Act capital raises which allows retail investors to invest in startups.

For more information visit www.ecitemotors.com/what-if

Direct links to the offering will be provided once it is open to the public.

This valuation was reached following E-Cite becoming the first (and only) vehicle manufacture under the Low Volume Manufacturers Act to receive approval from the California Air Resources Board (CARB) to proceed with the certification process that will allow it to manufacture and sell new EV vehicles in all 50 states.

The offering is expected to go live in the next couple of weeks and significant bonuses are being offered to early investors. The offering under the valuation is limited to $1,235,000 which once reached, the valuation is expected to increase significantly.

Gene Langmesser, E-Cite COO, stated: “Now that the engineering and designs are complete, and we have been approved to undergo CARB certification, we intend to move full speed ahead with our production vehicles. We are thrilled to be able to allow the public to invest directly in our progress and share in our success at our current valuation.”

Previously E-Cite was also the first company to get any vehicle approved by the National Highway Traffic Safety Administration (NHTSA) of which it has three distinctly different vehicles approved. This allows E-Cite to produce its own VINs for production of new vehicles. In addition, E-Cite was the first to receive a World Manufactures Identifier (WMI), registering it as a manufacturer for the sale of vehicles worldwide.

In anticipation that E-Cite’s prototype vehicle will become certified as a zero emissions compliant vehicle by CARB making it legal for sale in all 50 states, E-Cite is moving forward with its plan to begin manufacturing of its production vehicles. It is expected that all certifications will be completed in time for E-Cite’s launch of its production vehicles in the fourth quarter of 2023.

As this was the first time in history that a manufacture had reached the point of applying for certification from CARB under the Act, and there was no process in place to do so; E-Cite has worked closely with CARB while they defined the process, paving the way for future vehicles to go through the certification process.

Note* E-Cite's vehicles are in no way categorized as "Kit Cars" as they are manufactured new vehicles.

VaporBrands International Inc. (VAPR) Stock Research Links

VAPR Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 176

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 531

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Updated Category News Views 132

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 136

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 247

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 121

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 184

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 153

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 280

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading

Top 5 Most Recently Viewed Articles

Aalberts Shares Buyback Program Updates and Insights

Updated Category News Views 113

Overview of Aalberts' Share Buyback Program Aalberts has recently announced the progress of its ongoing share buyback program, giving investors and shareholders a detailed look into its current operations. This program is part of a strategic initiative to enhance shareholder value and demonstrate confidence in the company's long-term prospects. Recent Share Repurchase...

Continue Reading
American Water Named Among 2025 Most Responsible Companies

Updated Category News Views 206

American Water's Recognition on Newsweek’s List American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., is proud to announce its inclusion in Newsweek’s list of America’s Most Responsible Companies for 2025. This honor reflects American Water's unwavering commitment to environmental, social, and governance (ESG)...

Continue Reading
Pendulum Ink Reimagines Hip-Hop Education with New Model

Updated Category News Views 289

Pendulum Ink Innovates Online Hip-Hop Education Pendulum Ink, recognized as the world's first online hip-hop academy, has made headlines with its recent relaunch featuring a subscription-based model. This new structure is designed to provide flexible engagement tiers, making hip-hop education accessible to learners around the globe. The relaunch not only aims to educate...

Continue Reading
Revolutionizing Radiology: Mach7 Technologies Launches UnityVue

Updated Category News Views 90

Mach7 Technologies Introduces UnityVue for Radiology Mach7 Technologies is thrilled to announce the release of UnityVue, an advanced, AI-driven workflow orchestration solution designed to enhance patient care, alleviate radiologist burnout, and optimize diagnostic workflows. This innovative platform aims to create a more efficient radiology environment, making it a...

Continue Reading
Purina Partners with UC Davis to Enhance Pet Urinary Health

Updated Category News Views 150

Purina Teams Up with UC Davis School of Veterinary Medicine Nestlé Purina PetCare is thrilled to share a groundbreaking partnership with the University of California, Davis. This collaboration is focused on improving our understanding of urinary health in pets. With the support of a generous grant, this initiative represents a major step forward in scientific research...

Continue Reading